A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 145-153

  Norman, Andrew B ^a   Tabet, Michael R ^a   Norman, Mantana K ^a   Buesing, William R ^a   Pesce, Amadeo J ^a   Ball, William J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYLECGONINE; COCAINE; HEMOGLOBIN; HEPARIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2E2; MONOCLONAL ANTIBODY 3P1A6; MONOCLONAL ANTIBODY B4E10; PENTOBARBITAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY AFFINITY; AREA UNDER THE CURVE; ARTICLE; CHIMERA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; COCAINE; COCAINE-RELATED DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 33845889554     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.111781     Document Type: Article

References (38)

1. Abramowicz D, Crusiaux A, Niaudet P, Kreis H, Chatenoud L, and Goldman M (1996) The IgE humoral response in OKT3-treated patients: incidence and fine specificity. Transplantation 61:577-581.
2. Ball WJ, Kasturi R, Dey P, Tabet M, O'Donnell S, Hudson D, and Fishwild D (1999) Isolation and characterization of human monoclonal antibodies to digoxin. J Immunol 163:2291-2298.
3. 2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 49:277-281.
4. Benuck M, Lajtha A, and Reith MEA (1987) Pharmacokinetics of systemically administered cocaine and locomotor stimulation in mice. J Pharmacol Exp Ther 243:144-149.
5. Booze RM, Lehner AF, Wallace DR, Welch MA, and Mactutus CF (1997) Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. Neurotoxicol Teratol 19:7-15.
6. Carrera MR, Ashley JA, Parsons LH, Wirsching P, Koob GF, and Janda KD (1995) Suppression of psychoactive effects of cocaine by active immunization. Nature (Lond) 378:727-730.
7. Carrera MRA, Ashley JA, Wirsching P, Koob GF, and Janda KD (2001) A second generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA 98:1988-1992.
8. Carrera MRA, Ashley JA, Zhou B, Wirsching P, Koob GF, and Janda KD (2000) Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci USA 97:6202-6206.
9. Choudhri TF, Hoh BL, Solomon RA, Connolly ES, and Pinsky DJ (1997) Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice. Stroke 28:2296-2302.
10. de Villiers SHL, Lindblom N, Kalayanov G, Gordon S, Johansson AM, and Svensson TH (2004) Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat. Naunyn- Schmiedeberg's Arch Pharmacol 370:299-304.
11. DeWitt H and Stewart J (1981) Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology 75:134-143.
12. Ettinger RH, Ettinger WF, and Harless WE (1997) Active immunization with cocaine-protein conjugate attenuates cocaine effects. Pharmacol Biochem Behav 58:215-220.
13. Evans SM and Foltin RW (2004) Pharmacokinetics of intravenous cocaine across the menstrual cycle in rhesus monkeys. Neuropsychopharmacology 29:1889-1900.
14. Fox BS (1997) Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend 48:153-158.
15. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greenstein JL, et al. (1996) Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 2:1129-1132.
16. Keyler DE, Hieda Y, St Peter J, and Pentel PR (1999) Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res 1:241-249.
17. Keyler DE, Roiko SA, Benlhabib E, Lesage MG, St Peter JV, Stewart S, Fuller S, Le CT, and Pentel PR (2005) Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos 33:1056-1061.
18. Kosten TR and Owens SM (2005) Immunotherapy for the treatment of drug abuse. Pharmacol Ther 108:76-85.
19. Kosten TR, Rosen M, Bond J, Settles M, St. Clair Roberts J, Shields J, Jack L, and Fox B (2002) Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20:1196-1204.
20. Larsen NA, de Prada P, Deng S-X, Mittal A, Braskett M, Zhu X, Wilson IA, and Landry DW (2004) Crystallographic and biochemical analysis of cocaine-degrading antibody 15A10. Biochemistry 43:8067-8076.
21. Larsen NA, Zhou B, Heine A, Wirsching P, Janda KD, and Wilson IA (2001) Crystal structure of a cocaine-binding antibody. J Mol Biol 311:9-15.
22. Lau CE and Sun L (2002) The pharmacokinetic determinants of the frequency and pattern of intravenous cocaine self-administration in rats by pharmacokinetic modeling. Drug Metab Dispos 30:254-261.
23. Laurenzana EM, Byrnes-Blake KA, Milesi-Halle A, Gentry WB, Williams DK, and Owens SM (2003) Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab Dispos 31:1320-1326.
24. Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23:1117-1125.
25. Martell BA, Mitchell E, Poling J, Gonsai K, and Kosten TR (2005) Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58:158-164.
26. Matsushita M, Hoffman TZ, Ashley JA, Zhou B, Wirsching P, and Janda KD (2001) Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg Med Chem Lett 11:87-90.
27. Mets B, Winger G, Cabrera C, Seo S, Jamdar S, Yang G, Zhao K, Briscoe RJ, Almonte R, Woods JH, and Landry BW (1998) A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc Natl Acad Sci USA 95:10176-10181.
28. 3H] cocaine in acutely and chronically treated monkeys. Drug Alcohol Depend 2:261-272.
29. Norman AB, Norman MK, Hall JF, and Tsibulsky VL (1999) Priming threshold: a novel quantitative measure of the reinstatement of cocaine self-administration. Brain Res 831:165-174.
30. Norman AB, Welge JA, and Tsibulsky VL (2002) Characterization of the distribution of the cocaine priming threshold and the effect of SCH23390. Brain Res 946:253-261.
31. Paula S, Tabet MR, Farr CD, Norman AB, and Ball WJ (2004) Modeling of cocaine binding by a novel human monoclonal antibody. J Med Chem 47:133-142.
32. Paula S, Tabet MR, Keenan SM, Welsh WJ, and Ball WJ (2003) Three-dimensional structure-activity relationship modeling of cocaine binding to two monoclonal antibodies by comparative molecular field analysis. J Mol Biol 325:515-530.
33. Proksch JW, Gentry WB, and Owens SM (2000) Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 292:831-837.
34. Redwan E-R, Larsen NA, Zhou B, Wirsching P, Janda KD, and Wilson IA (2003) Expression and characterization of a humanized cocaine-binding antibody. Biotechnol Bioeng 82:612-618.
35. Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, and Owens SM (1996) Anti-phencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther 278:709-716.
36. Valentine JL and Owens SM (1996) Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther 278:717-724.
37. Vocci L and Ling W (2005) Medications development: successes and challenges. Pharmacol Ther 108:94-108.
38. Warner A and Norman AB (2000) Mechanisms of cocaine hydrolysis and metabolism in vitro and in vivo: a clarification. Ther Drug Monit 22:266-270.